Arianna Pani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arianna Pani has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Sartore-Bianchi
Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
1 shared publication - Elio Gregory Pizzutilo
Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
1 shared publication - Federica Tosi
Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
1 shared publication - Federica Villa
Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
1 shared publication - Francesco Scaglione
CNR Institute of Clinical Physiology (IFC-CNR), ASST GOM Niguarda, Piazza dell’Ospedale Maggiore 3, 20162 Milan, Italy
1 shared publication - Gianluca Gazzaniga
Department of Medical Biotechnologies and Translational Medicine, Post-Graduate School of Pharmacology and Clinical Toxicology, University of Milan, 20122 Milan, Italy
1 shared publication
Latest Publications
- Open Access
Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review
Pneumatosis intestinalis (PI) is a rare condition due to the presence of gas within the bowel wall; it is mainly caused by endoscopic procedures, infections and other gastrointestinal diseases. Oncological therapies have been reported to be a cause of PI as well, but their role is not clearly defined. This systematic review investigates the concurrency of PI and antitumor therapy in cancer patients, considering both solid tumors and onco-hematological ones. We performed a literature review of PubMed, Embase and the Web of Science up to September 2021 according to the PRISMA guidelines. A total of 62 papers reporting 88 different episodes were included. PI was mainly reported with targeted therapies (sunitinib and bevacizumab above all) within the first 12 weeks of treatment. This adverse event mostly occurred in the metastatic setting, but in 10 cases, it also occurred also in the neoadjuvant and adjuvant setting. PI was mostly localized in the large intestine, being fatal in 11 cases, while in the remaining cases, symptoms were usually mild, or even absent. A significant risk of PI reoccurrence after drug reintroduction was also reported (6/18 patients), with no fatal outcomes. Potential pharmacological mechanisms underlying PI pathogenesis are also discussed. In conclusion, although uncommonly, PI can occur during oncological therapies and may lead to life-threatening complications; therefore, consideration of its occurrence among other adverse events is warranted in the presence of clinical suspicion.
Open AccessPneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review
Pneumatosis intestinalis (PI) is a rare condition due to the presence of gas within the bowel wall; it is mainly caused by endoscopic procedures, infections and other gastrointestinal diseases. Oncological therapies have been reported to be a cause of PI as well, but their role is not clearly defined. This systematic review investigates the concurrency of PI and antitumor therapy in cancer patients, considering both solid tumors and onco-hematological ones. We performed a literature review of PubMed, Embase and the Web of Science up to September 2021 according to the PRISMA guidelines. A total of 62 papers reporting 88 different episodes were included. PI was mainly reported with targeted therapies (sunitinib and bevacizumab above all) within the first 12 weeks of treatment. This adverse event mostly occurred in the metastatic setting, but in 10 cases, it also occurred also in the neoadjuvant and adjuvant setting. PI was mostly localized in the large intestine, being fatal in 11 cases, while in the remaining cases, symptoms were usually mild, or even absent. A significant risk of PI reoccurrence after drug reintroduction was also reported (6/18 patients), with no fatal outcomes. Potential pharmacological mechanisms underlying PI pathogenesis are also discussed. In conclusion, although uncommonly, PI can occur during oncological therapies and may lead to life-threatening complications; therefore, consideration of its occurrence among other adverse events is warranted in the presence of clinical suspicion.